Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis but do not necessarily predict treatment failure

British Journal of Dermatology

Volumn 164, Issue 2, 2011, Pages 459-460

  Golberg, O ^a   Osborne, J E ^a   Hutchinson, P E ^a  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNOTHERAPY; LETTER; PRIORITY JOURNAL; PSORIASIS; TREATMENT FAILURE;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; HUMANS; PREDICTIVE VALUE OF TESTS; PSORIASIS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551473757     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10101.x     Document Type: Letter

References (2)

1. Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-α therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010; 162: 780-5.
2. Romero-Maté A, García-Donoso C, Cõrdoba-Guijarro S,. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007; 8: 143-55.